公开(公告)号：US11208418B2

公开(公告)日：2021-12-28

申请号：US16962080

申请日：2019-01-28

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xinye Yang ,  Xiaojun Wang ,  Junwen Wu ,  Hong Chen ,  Shengtian Cao ,  Yingjun Zhang

IPC: C07D491/044 ,  C07D491/147 ,  C07D498/14 ,  C07D471/04 ,  C07D491/056 ,  A61K31/554 ,  A61K31/55 ,  A61K31/519

Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.

公开(公告)号：US10266496B2

公开(公告)日：2019-04-23

申请号：US15750205

申请日：2016-08-31

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xinye Yang ,  Changwei Huang ,  Facheng Ma ,  Ji Zhang ,  Xiaojun Wang ,  Yingjun Zhang

IPC: C07D215/48 ,  C07D215/02 ,  C07D235/08 ,  C07D237/28 ,  C07D249/18 ,  C07D261/20 ,  C07D263/54 ,  C07D209/04 ,  C07D291/08 ,  C07D263/56 ,  C07D317/64 ,  C07D231/56 ,  C07D333/54 ,  C07D333/62 ,  C07D235/06 ,  C07D471/04 ,  C07D487/04 ,  C07D209/08 ,  C07D209/10 ,  C07D277/64 ,  C07D209/30 ,  C07D307/79 ,  C07D307/82 ,  C07D209/42 ,  C07D213/79 ,  C07D215/06 ,  C07D215/16 ,  C07D215/18 ,  C07D237/30 ,  C07D277/56 ,  C07D307/83 ,  C07D307/84 ,  C07D307/85 ,  C07D317/68 ,  C07D333/70 ,  C07D405/04 ,  A61K31/33 ,  A61K31/404 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/517 ,  A61K31/519 ,  A61K31/277 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/502 ,  A61K45/06 ,  C07C255/57 ,  A61K31/47 ,  A61P13/02

Abstract: Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

公开(公告)号：US10183917B2

公开(公告)日：2019-01-22

申请号：US15541018

申请日：2016-02-05

Applicant: Sunshine Lake Pharma Co., Ltd.

Inventor： Xiaojun Wang ,  Xinye Yang ,  Shengqiang Pan ,  Rui Guo ,  Junwen Wu ,  Yingjun Zhang ,  Changchung Cheng

IPC: C07D261/08 ,  C07D249/06 ,  A61K31/42 ,  A61K31/4353 ,  A61K31/4985 ,  A61K31/519 ,  C07D411/12 ,  C07D413/12 ,  C07D471/04 ,  C07D491/044 ,  C07D497/04 ,  C07D498/14 ,  C07D491/052 ,  C07D491/147 ,  C07D498/04

Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

公开(公告)号：US11242335B2

公开(公告)日：2022-02-08

申请号：US16500266

申请日：2018-04-10

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yinglin Zuo ,  Xiaojun Wang ,  Chuanwen Yang ,  Jiancheng Wang ,  Shengtian Cao ,  Fangyuan Wu ,  Yingjun Zhang ,  Siegfried Goldmann

IPC: C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: A class of fluorine-substituted indazole compounds and uses thereof having the general formula depicted below in which C1 is where is the bond through which C1 is attached to L, and C2 is where is the bond through which C2 is attached to indazole, and pharmaceutical compositions containing these compounds. The compounds and pharmaceutical compositions of the invention can be used as soluble guanylate cyclase simulators.

公开(公告)号：US10065928B2

公开(公告)日：2018-09-04

申请号：US15502499

申请日：2015-09-01

Applicant: Sunshine Lake Pharma Co., Ltd.

Inventor： Yinglin Zuo ,  Xiaojun Wang ,  Yingjun Zhang ,  Liang Wen ,  Shoutao Wu ,  Xiaofeng Yuan

IPC: C07D215/56 ,  C07D215/54 ,  C07D401/04 ,  C07D401/12 ,  C07D413/12 ,  A61P9/10 ,  A61P7/06

Abstract: Provided herein are a quinolinone compound, pharmaceutical composition thereof, and use of the compound or the pharmaceutical composition in drug preparation, the drug being used to prevent, manage, treat or relieve diseases related to HIF and/or EPO of a patient, including anemia, vascular disease, myocardial ischemia, dysmetabolism, or for wound healing.

公开(公告)号：US09434695B2

公开(公告)日：2016-09-06

申请号：US14396754

申请日：2013-07-18

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun Zhang ,  Jiancun Zhang ,  Xiaojun Wang ,  Runfeng Lin ,  Shengtian Cao ,  Zhaohe Wang ,  Jing Li

IPC: C07D239/36 ,  C07D403/12 ,  C07D401/12 ,  C07D403/06 ,  C07D405/12 ,  C07D417/04 ,  C07D498/04 ,  C07D213/64

CPC classification number: C07D239/36 ,  C07D213/64 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D417/04 ,  C07D498/04

Abstract: The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

公开(公告)号：US10562910B2

公开(公告)日：2020-02-18

申请号：US16322945

申请日：2017-08-02

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xiaojun Wang ,  Xinye Yang ,  Junwen Wu ,  Shaohui Xiong ,  Shengqiang Pan ,  Shengtian Cao ,  Yingjun Zhang

IPC: C07D491/044 ,  C07D491/056 ,  A61K31/4164 ,  A61P9/04 ,  A61K31/4353 ,  A61P15/00 ,  A61P5/50 ,  A61P9/12 ,  A61P7/02 ,  A61P9/10 ,  A61K31/42 ,  C07D491/107

Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

公开(公告)号：US10851068B2

公开(公告)日：2020-12-01

申请号：US16627966

申请日：2018-07-03

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Runfeng Lin ,  Xiaojun Wang ,  Jihua Lin ,  Liang Chen ,  Yingjun Zhang ,  Jiancun Zhang

IPC: C07D239/36 ,  C07D211/50 ,  C07C211/50

Abstract: A method for preparing a pyrimidone compound and an important intermediate in which raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation method is simple to operate, and is safe and controllable, has high total yield, and thus is suitable for industrial production.

公开(公告)号：US10759812B2

公开(公告)日：2020-09-01

申请号：US16476290

申请日：2018-01-22

Applicant: SUNSHINE LAKE PHARMA CO., LTD. ,  NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED

Inventor： Wanjun Tang ,  Xinye Yang ,  Zheng Gu ,  Chenlu Li ,  Zongyuan Zhang ,  Zhifu Wan ,  Xiaojun Wang ,  Yingjun Zhang

IPC: C07D495/04 ,  C07D519/00 ,  A61K31/519 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P35/00

Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.

公开(公告)号：US10647682B2

公开(公告)日：2020-05-12

申请号：US16316055

申请日：2017-07-19

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Runfeng Lin ,  Liang Chen ,  Xiaojun Wang ,  Yingjun Zhang ,  Jiancun Zhang

IPC: C07D239/22 ,  C07C57/145 ,  C07C317/22 ,  A61P13/08 ,  A61P1/16 ,  A61P13/12 ,  A61P17/00 ,  A61K31/513 ,  A61P25/28 ,  A61P1/18 ,  A61P11/00 ,  A61P43/00 ,  C07D239/36

Abstract: Provided are salts of 2,6-dimethylpyrimidone derivatives and uses thereof. Also provided are pharmaceutical compositions containing the salts.